Beyond Today’s Implants: The Next Generation of Sustained Drug Delivery
By
Ciera D. Johnson, BS
Rachel Chapman
Samantha Goldburg, MD
Mary Qiu, MD,
September 1, 2026
Clinical Scorecard: Beyond Today’s Implants: The Next Generation of Sustained Drug Delivery
At a Glance
Category Detail
Condition Glaucoma Management Key Mechanisms Sustained drug delivery via intracameral implants and biodegradable platforms. Target Population Patients with glaucoma requiring long-term intraocular pressure management. Care Setting Clinical settings involving glaucoma treatment and management.
Key Highlights
Medication adherence is a significant challenge in glaucoma management. Durysta and iDose TR provide continuous drug delivery without daily administration. Biodegradable implants like PA5108 show promise for repeat treatment without permanent materials. The BIM-IOL system offers sustained therapy integrated into cataract surgery. Ongoing trials are necessary to establish the clinical roles of new drug delivery systems. Guideline-Based Recommendations
Diagnosis
Assess intraocular pressure and visual field progression in glaucoma patients. Management
Consider sustained drug delivery systems for patients with adherence issues. Monitoring & Follow-up
Regularly evaluate intraocular pressure and corneal endothelial health. Risks
Monitor for ocular surface disease and potential complications from implants. Patient & Prescribing Data
Patients with glaucoma, particularly those struggling with medication adherence.
Sustained drug delivery may improve adherence and reduce the burden of complex regimens.
Clinical Best Practices
Evaluate angle anatomy before implanting permanent devices. Consider patient history and potential for ocular surface disease when prescribing treatments. Stay updated on emerging technologies and clinical trial results for new drug delivery systems. Related Resources & Content
